Furthermore, since increased YAP/TAZ activities can trigger epithelial-mesenchymal transition (EMT)[97-101], a YAP/TAZ antagonist might influence the cellular plasticity in carcinomas, thereby decreasing therapeutic resistance, tumour recurrence and metastatic progression[102,103]. The gene discussed is YAP1; the disease is neoplasm.